Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

Last updated: March 18, 2025
Sponsor: Vanda Pharmaceuticals
Overall Status: Completed

Phase

3

Condition

Vomiting

Treatment

Placebo

Tradipitant

Clinical Study ID

NCT05903924
VP-VLY-686-3404
  • Ages 18-75
  • All Genders

Study Summary

A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • History of motion sickness

  • Age 18-75

Exclusion

Exclusion Criteria:

  • Nausea-inducing disorder other than motion sickness

  • BMI>40

  • History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists

Study Design

Total Participants: 316
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 3
Study Start date:
September 09, 2023
Estimated Completion Date:
April 24, 2024

Connect with a study center

  • Pacific Research Partners

    San Diego, California 94607
    United States

    Site Not Available

  • Lumos Clinical Research

    San Jose, California 95124
    United States

    Site Not Available

  • Santa Monica Clinical Trials

    Santa Monica, California 90404
    United States

    Site Not Available

  • Beacon Clinical Research

    Boston, Massachusetts 02169
    United States

    Site Not Available

  • Manhattan Medical Research

    New York, New York 10016
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.